ProPhase Labs reported its progress on the commercialization of its BE-Smart test for esophageal cancer. The Company is aiming for commercial launch in the second half of 2024. Ted Karkus, CEO of ProPhase Labs, commented, “The BE-Smart test is more than an advancement in medical technology; it is providing a critical solution to esophageal cancer by enabling early and cost-effective detection. Early detection offers patients the opportunity for more favorable outcomes and a brighter, healthier future. This groundbreaking diagnostic test is a patent-protected method for identifying esophageal cancer markers and a key component of ProPhase Labs’ mission to enhance early detection and facilitate personalized treatment strategies and reflects our commitment to saving lives and improving patient care.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRPH:
- ProPhase Labs Seeks to Transform Esophageal Cancer Detection and Management with Launch of its BE-Smart Test in H2 2024
- ProPhase Labs Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- ProPhase Labs rating moved to under review at H.C. Wainwright
- ProPhase Labs sees significant sequential improvement in revenues going forward
- ProPhase Labs reports 2023 EPS (98c) vs. $1.02 last year